A.V. VOROBIEV, A.D. MAKATSARIYA

First Moscow State Medical University named after I.M. Sechenov, 2 Pirogovskaya St., b.4, Moscow, Russian Federation, 119991

Vorobiev A.V. — Cand. Med. Sc., Associate Professor of the Department of Obstetrics and Gynecology of Public Health Faculty, tel. +7-903-105-63-65, e-mail: alvorobev@gmail.com

Makatsariya A.D. — Corresponding Member of the Russian Academy of Medical Sciences, Professor, D. Med. Sc., Head of the Department of Obstetrics and Gynecology of Public Health Faculty, tel. +7-903-08-97, e-mail: gemostasis@mail.ru 

The article describes the main anticoagulant drugs used for patients with cancer, taking into consideration the pathogenetic aspects of hypercoagulation status in oncologic patients: oral anticoagulants, heparin drugs, selective factor Xa inhibitors. The main advantages of low molecular weight heparin as compared with unfractioned heparin are described. The article provides a comparison of low-molecular weight heparin drugs, their generics and biosimilar drugs. Recommendations on prevention of thrombotic complications in cancer patients are provided. An overview of the possible complications of heparin therapy and methods of their prevention is presented.

Key words: low molecular weight heparin, oral anticoagulants, heparin induced thrombocytopenia, thrombosis prophylaxis, factor Xa inhibitors.

 

 

REFERENCES

1. Gray E., Mulloy B., Barrowcliffe T.W. Heparin and low-molecularweight heparin. Thromb Haemost., 2008, vol. 99, rr. 807-18.

2. Makatsariya A.D., Vorob’ev A.V., Bitsadze V.O. Zlokachestvennye novoobrazovaniya, trombofiliya, trombozy [Malignant neoplasm, thrombophilia, thrombosis]. Moscow: Triada-Kh, 2008. 650 p.

3. Donati M.B., A. Falanga: Patogenetic Mechanisms of Thrombosis in Malignancy. Acta Haematol., 2001, vol. 106, rr. 18-24.

4. van Dongen C.J., Mac Gillavry M.R., Prins M.H. Once versus twice daily LMWH for the initial treatment of venous thromboembolism. Cochrane Database Syst. Rev., 2005, issue 3, art. no. CD003074.

5. Falanga A., Marchetti M., Vignoli A. Pathogenesis of thrombosis in cancer. Thromb and cancer, 2004, vol. 30, rr. 11-23.

6. Bogenrieder T., Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene, 2003, vol. 22, rr. 6524-36.

7. Lee A.Y.Y. Screening for occult cancer in patients with idiopathic venous thromboembolism. J Thromb Haemost., 2003, vol. 1, rr. 2273-2274.

8. Vorob’ev A.V. Malignant disease and thrombosis. Voprosy akusherstva, ginekologii i perinatologii, 2008, vol. 7, no. 2, pp. 18-25 (in Russ.).

9. Tsyb A.F., Sushkevich G.N., Baluda M.V., Vorob’ev A.V., Chabrov A.M. Printsipy profilaktiki tromboticheskikh oslozhneniy u onkologicheskikh bol’nykh (solidnye obrazovaniya). Posobie dlya vrachey [Principles of prevention of thrombotic complications in patients with cancer (solid tumors). Manual for physicians]. Obninsk, 2008. 42 p.

10. Gray E., Rigsby P., Behr-Gross M.E. Collaborative study to establish the low-molecular-mass heparin for assay – European Pharmacopoeia Biological Reference Preparation. Pharmeuropa Bio, 2004, vol. 1, rr. 59-76.

11. Makatsariya A.D. et al. Trombogemorragicheskie oslozhneniya v akushersko-ginekologicheskoy praktike. Rukovodstvo dlya vrachey pod redaktsiey A.D. Makatsariya [Thrombohemorrhagic complications in obstetric practice. Guide for Physicians, edited by A.D. Makatsaria]. MIA, Moscow, 2011.

12. Shilova A.N., Lazarev A.F., Vorob’ev P.A., Barkagan Z.S., Khodorenko S.A., Kotovshchikova E.F., Momot A.P., Buevich E.I. Controlled antithrombotic prophylaxis onkotrombozov: clinical and economic analysis. Sibirskiy onkologicheskiy zhurnal, 2008, no. 3, pp. 74-76 (in Russ.).

13. Zacharski Leo R. Malignancy as a solid-phase coagulopathy: implications for the etiology, pathogenesis, and treatment of cancer. Seminars in thrombosis and hemostasis, 2003, vol. 29, rr. 239-46.

14. Kakkar A.K., Levine M.N., Kadziola Z. et al. Low molecular weight heparin therapy with dalteparin and survival in advanced cancer the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J. Clin. Oncol., 2004, vol. 22, no. 10, pp. 1944-1948.

15. Prandoni P., Lensing A.W., Piccioli A. et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002, vol. 100, no. 10, pp. 3484-3488.

16. Samama M.M., Gerotziafas G. Comparative Pharmacokinetics of LMWHs. Semin Thromb Hemost., 2000, vol. 26, rr. 31-6.

17. Guerrini M., Guglieri S., Naggi A., Sasisekharan R., Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost., 2007, vol. 33, rr. 478-87.

18. ENOXACAN Study Group. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. Br J Surg., 1997, Aug., vol. 84 (8), rr. 1099-103.

19. David Bergqvist, M.D., Ph.D., Giancarlo Agnelli, M.D., Alexander T. Cohen, M.D., Amiram Eldor, M.D., Paul E. Nilsson, M.D., Ph.D., Anne Le Moigne-Amrani, M.S., and Flavia Dietrich-Neto, M.D. for the ENOXACAN II Investigators. Duration of Prophylaxis against Venous Thromboembolism with Enoxaparin after Surgery for Cancer. N Engl J Med., 2002, vol. 346, rr. 975-980.

20. Agnes Y.Y. Lee, M.D., Mark N. Levine, M.D., Ross I. Baker, M.D., Chris Bowden, M.D., Ajay K. Kakkar, M.B., Martin Prins, M.D., Frederick R. Rickles, M.D., Jim A. Julian, M.Math., Susan Haley, B.Sc., Michael J. Kovacs, M.D., and Michael Gent. Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer. N Engl J Med., 2003, vol. 349, rr. 146-153.

21. Klerk C.P.W., Smorenburg S.M., Otten H.M. et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol., 2005, vol. 23, no. 10, pp. 2130-2135.

22. FDA News Release, July 23, 2010. fda.gov/NewsEvents/News-roorn/PressAnnouncements/ucm220092.hm. Accessed July 23, 2010.

23. Meyer G., Marjanovic Z., Valcke J. et al. Comparison of low molecular weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer a randomized controlled study. Arch. Intern. Med., 2002, 162, no. 15, pp. 1729-1735.

24. EMEA. Guidelines on Clinical and Non-Clinical Development of Medicinal Products Containing Low-Molecular-Weight Heparins. London: European Medical Agency; 2009. EMEA/CHMP/ BMWP/11826407enfin.pdf. Accessed July 29, 2010.

25. Hirsh J., Warkentin T.E., Shaughnessy S.G. et al. Heparin and lowmolecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 2001, vol. 119: suppl. 1, rr. 64S-94S.

26. Rossiyskie klinicheskie rekomendatsii po diagnostike, lecheniyu i profilaktike venoznykh tromboembolicheskikh oslozhneniy. Assotsiatsiya flebologov Rossii, Vserossiyskoe obshchestvo khirurgov [Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic complications. Russian Association of Phlebology, All-Russian Society of Surgeons]. Moscow: Media Sfera, 2010.

27. Samama M.M. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med., 2000, vol. 160, rr. 3415-20.

28. Makatsariya A. D., Vorob’ev A.V., Chabrov A.M. Znachenie otsenki markerov trombofilii pri provedenii khimio- i luchevoy terapii u onkologicheskikh bol’nykh. Materialy Rossiyskogo meditsinskogo foruma – 2006 “Fundamental’naya nauka i praktika” [The assessment of markers of thrombophilia during chemotherapy and radiotherapy in cancer patients. Proceedings of the Russian Medical Forum – 2006 «Fundamental science and practice»]. 18-20 October, 2006.

29. North American Thrombosis Forum Official Policy Statement regarding the protection of patient safety and patient rights on the matter of follow-on biologies. natfonIine.org/NATFbiologiessta-tement.php. Accessed July 26, 2010.

30. WHO 2009. Guidelines on evaluation of similar biotherapeutic products (SBPs). who.int/biologicaIs/areas/biologicaI_thcrapeutic/BIOTHERAPETUTICS_FOR_WEB_22APRIL2010_WI. Accessed August 18, 2010.

31. Drugs. Establishing Active Ingredient Sameness for Generic Enoxaparin Sodium, a Low Molecular Weight Heparin. Accessed July 28, 2010.

32. Harenberg J., Kakkar A., Bergqvist D. et al. on behalf of the Subcommittee on Control of Anticoagulalion of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemoslasis. Recommendations on biosimiliar low-molecular-weight heparins. J Thromb Haemost., 2009, vol. 7 (7), rr. 1222-1225.

33. Kalodiki E., Leon W. SASAT and Task Force on Generic LMWHs. SASAT (South Asian Society on Atherosclerosis and Thrombosis) proposal for regulatory guidelines for generic low molecular weight heparins (LMWHs). ClinApplThrombHemost., 2009, vol. 15 (1), rr. 8-11.

34. Prandoni P., Falanga A., Piccioli A. Cancer and venous thromboembolism. Lancet Oncol., 2005, Jun., vol. 6 (6), rr. 401-10.

35. Prandoni P., Lensing A.W., Buller H.R. et al. Deep vein thrombosis and the incidence of subsequent symptomatic cancer. N. Engl. J. Med., 1992, vol. 327, no. 16, pp. 1128-1133.